CRISPR Therapeutics AG (CRSP)
| Market Cap | 6.02B |
| Revenue (ttm) | 14.82M |
| Net Income (ttm) | -633.45M |
| Shares Out | 78.01M |
| EPS (ttm) | 3.76 |
| PE Ratio | 20.53 |
| Forward PE | 23.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 473,674 |
| Open | 80.11 |
| Previous Close | 80.14 |
| Day's Range | 75.37 - 80.47 |
| 52-Week Range | 42.51 - 129.50 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 116.77 (+51.2%) |
| Earnings Date | Aug 4, 2022 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidat... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 32 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 116.77, which is an increase of 51.24% from the latest price.
News
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines an...
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the...
Where Will CRISPR Therapeutics Be in 1 Year?
The next 12 months could look very different from the past year for this biotech company.
2 Biotech Stocks to Help Recession-Proof Your Portfolio
These companies' shares have outpaced the market and other biotech stocks this year.
The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common
They are also outperforming the S&P 500.
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week
These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These players may change the world of medicine.
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.
Should You Sell Biotech Stocks If There's a Recession?
It's probably better to think about whether to buy more shares.
Why CRISPR Therapeutics Stock Is Falling
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day. CRISPR Therapeutics stock plun...
Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?
CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the broader ...
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner
CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets. The CRISPR Ther...
3 Bargain Stocks You Can Buy Today and Hold Forever
These companies have become great deals because of the market downturn.
Final Trades: Boeing, Charles Schwab, Crispr Therapeutics & more
The "Halftime Report" traders give their top picks to watch for the second half.
2 Top Biotech Stocks Ready for Bull Runs
The market hasn't been kind to these two stocks lately.
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic ...
Roku, Tesla, and Other Cathie Wood Favorites Are Falling
The ARK Innovation ETF has fallen about 65% in the past year as investors fled from growth stocks.